HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)

The study results suggest that A2B1 plays a crucial role in IBD by modulating TRAIL mRNA, leading to IECs apoptosis and intestinal barrier dysfunction. Targeting the A2B1-TRAIL interaction with small-molecule inhibitors like TeGG offers a novel and promising therapeutic approach for the treatment of IBD.

Combined use of circESR1 ASO and CDK4/6 inhibitors were shown to be an effective therapeutic approach overcoming antiestrogen resistance in breast cancer xenograft models. Hence, these findings elucidated a novel signaling complex centered around circESR1 and HNRNPAB in ER+ breast cancer, and suggested that circESR1 might represent a potential therapeutic target for this disease.

Furthermore, HNRNPA2B1 targeted the LDHA mRNA m6A modified site to enhance LDHA mRNA stability and lactate accumulation, thereby assisted NSCLC cells to evade CD8+ T antitumor immunity and reduced IFN-γ secretion by CD8+ T. Furthermore, IFN-γ could stimulate ferroptosis of NSCLC cells. Taken together, these findings revealed an important role for HNRNPA2B1 on NSCLC immune escape and ferroptosis resistance, which provided novel insight into m6A modification in NSCLC.

Overall, a tRF-22-hnRNPAB-TGFβ2-PMN-MDSCs-CD8+ T cell pathway is identified that drives immunosuppression and tumor growth. Targeting tRF-22 may be a promising strategy to improve immunotherapy efficacy in ESCC.

Our findings reveal the limitations of current splicing-prediction tools in recognizing exonic-splicing enhancer (ESE) or silencer (ESS) sequences and suggest that mutations can differentially affect disease phenotypes by influencing both splicing and protein stability. These insights enhance our understanding of the molecular mechanisms underlying VHL-associated disorders and expand the landscape of regulatory elements and protein factors involved in VHL splicing regulation.

SIGNIFICANCE STATEMENT: This exploratory study reveals that heterogeneous nuclear ribonucleoprotein A/B is associated with gastric cancer progression and epithelial-mesenchymal transition through its potential modulation of the Akt-GSK3β-Wnt signaling pathway. Targeting heterogeneous nuclear ribonucleoprotein A/B could offer novel therapeutic approaches for improving treatment outcomes in gastric cancer, highlighting its potential as a biomarker for disease prognosis.

Redox Signal. 00, 000-000.

Subsequently, EVs were transmitted to human lymphatic endothelial cells, and EVs carrying circPDLIM5 could then directly interact with the transcription factor Yin Yang 1 to enhance the expression of Prospero homeobox 1, which is crucial for the formation, differentiation, and maturation of lymphatic vessels. Our findingshighlight the importance of a molecular mechanism mediated by EVs carrying circPDLIM5that is involved in lymphangiogenesis and LN metastasis in PCa; as a result, EVscarrying circPDLIM5 may be an attractive therapeutic target for LN-metastatic PCa.

Additionally, MAGOH knockdown rescued circSRPK1-mediated RONΔ160 formation and GC malignancy. Overall, our research revealed a novel mechanism by which the MAGOH-circSRPK1-hnRNPA2B1-RONΔ160 axis regulated GC cell proliferation and metastasis, broadening the current understanding of circRNA-mediated regulation of tumor progression through aberrant alternative splicing.

These findings establish KAP1 as a critical driver of tumor progression in GAC through YAP1 regulation and HNRNPAB interaction, highlighting its potential therapeutic target. This study advances our understanding and offers a preclinical framework to improve outcomes for GAC.

Increasing the ionic strength to 0.1 mM significantly enhanced protein adsorption (Δf/n = -69 Hz). These findings emphasize the role of the PEI layer structure in optimizing protein immobilization, paving the way for further exploration of RBPs and their ligands.

Furthermore, elevated HNRNPA2B1 levels conferred resistance to multiple chemotherapeutics, including Dasatinib. Functional studies demonstrated that HNRNPA2B1 enhances lung cancer cell proliferation and migration by upregulating TARDBP and cell cycle-related genes, with m6A modification serving as a critical regulatory mechanism. Collectively, these findings establish HNRNPA2B1 as an oncogenic factor across multiple cancer types, underscoring its value as a prognostic marker and a promising therapeutic target, particularly in lung cancer, offering new insights for targeted therapeutic strategies.